HK1208152A1 - 用於治療癌症的涉及針對密蛋白 之抗體的聯合治療 - Google Patents
用於治療癌症的涉及針對密蛋白 之抗體的聯合治療Info
- Publication number
- HK1208152A1 HK1208152A1 HK15108682.9A HK15108682A HK1208152A1 HK 1208152 A1 HK1208152 A1 HK 1208152A1 HK 15108682 A HK15108682 A HK 15108682A HK 1208152 A1 HK1208152 A1 HK 1208152A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- treatment
- combination therapy
- antibodies against
- therapy involving
- Prior art date
Links
- 102000002029 Claudin Human genes 0.000 title 1
- 108050009302 Claudin Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/002210 WO2013174403A1 (en) | 2012-05-23 | 2012-05-23 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
PCT/EP2013/001504 WO2013174510A1 (en) | 2012-05-23 | 2013-05-21 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208152A1 true HK1208152A1 (zh) | 2016-02-26 |
Family
ID=48483023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108682.9A HK1208152A1 (zh) | 2012-05-23 | 2015-09-07 | 用於治療癌症的涉及針對密蛋白 之抗體的聯合治療 |
Country Status (25)
Country | Link |
---|---|
US (2) | US20150132253A1 (zh) |
JP (2) | JP6203831B2 (zh) |
KR (3) | KR102625189B1 (zh) |
CN (2) | CN104379166B (zh) |
AR (2) | AR091130A1 (zh) |
AU (2) | AU2013265638B2 (zh) |
BR (1) | BR112014028948B8 (zh) |
CA (1) | CA2874032A1 (zh) |
DK (2) | DK2852408T3 (zh) |
ES (2) | ES2835073T3 (zh) |
FI (1) | FI3791896T3 (zh) |
HK (1) | HK1208152A1 (zh) |
HR (2) | HRP20240169T1 (zh) |
HU (2) | HUE054214T2 (zh) |
IL (2) | IL235607A0 (zh) |
LT (3) | LT2852408T (zh) |
MX (5) | MX2014014216A (zh) |
NZ (2) | NZ701585A (zh) |
PT (3) | PT3254695T (zh) |
RS (2) | RS65179B1 (zh) |
RU (1) | RU2665321C2 (zh) |
SG (2) | SG11201406977TA (zh) |
SI (2) | SI3791896T1 (zh) |
UA (1) | UA118013C2 (zh) |
WO (2) | WO2013174403A1 (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
MX369276B (es) | 2012-11-13 | 2019-11-04 | Biontech Ag | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. |
WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2015142293A1 (en) * | 2014-03-21 | 2015-09-24 | Agency For Science, Technology And Research | Fusion genes in cancer |
WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
EP3471767A4 (en) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | INFLUENZA VIRUS HEMAGGLUTININS AND USES THEREOF |
CN109844125A (zh) * | 2016-08-31 | 2019-06-04 | 南京凯地生物科技有限公司 | 人pd-1基因敲除的cldn18.2特异性嵌合抗原受体t细胞的制备方法以及应用 |
EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES |
JP7216104B2 (ja) * | 2017-12-27 | 2023-01-31 | イミュナミ ラボラトリーズ プライベート リミティド | 組換えポリペプチドおよびその使用方法 |
US10150801B1 (en) | 2017-12-27 | 2018-12-11 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
EP3762031A4 (en) * | 2018-03-08 | 2021-12-22 | Phanes Therapeutics, Inc. | ANTI-CLAUDINE ANTIBODIES 18.2 AND THEIR USES |
US11059887B2 (en) * | 2018-05-18 | 2021-07-13 | Lanova Medicines Limited Company | Anti-claudin 18.2 antibodies and uses thereof |
WO2020038404A1 (zh) * | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
US20220033491A1 (en) * | 2018-09-30 | 2022-02-03 | Cafa Therapeutics Limited | Combination therapy of cldn18 antibody and chemotherapy drugs |
KR20210088632A (ko) * | 2018-11-08 | 2021-07-14 | 인8바이오 인코포레이티드 | 암의 치료용 조성물 및 치료 방법 |
JP2022515487A (ja) * | 2018-12-28 | 2022-02-18 | ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド | クローディン18.2結合部分およびその利用 |
EP3904386A4 (en) * | 2018-12-28 | 2022-09-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | ANTIBODIES AND USE THEREOF |
JP2022528061A (ja) * | 2019-04-01 | 2022-06-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 抗クローディン18.2抗体及びその用途 |
CA3137160A1 (en) * | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
WO2020238730A1 (zh) * | 2019-05-24 | 2020-12-03 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
CN114026125B (zh) * | 2019-07-12 | 2022-09-20 | 明济生物制药(北京)有限公司 | Cldn18.2抗体及其用途 |
US10675332B1 (en) | 2019-08-26 | 2020-06-09 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2021198157A1 (en) | 2020-03-30 | 2021-10-07 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2023025147A1 (zh) * | 2021-08-23 | 2023-03-02 | 南通壹宸生物医药科技有限公司 | 抗原表位修饰 |
CN113788894B (zh) * | 2021-09-03 | 2022-08-05 | 深圳市先康达生命科学有限公司 | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP2330130B1 (en) | 2002-10-17 | 2014-08-27 | Genmab A/S | Human monoclonal antibodies against CD20 |
MXPA06011903A (es) * | 2004-04-16 | 2007-03-21 | Emisphere Tech Inc | 8-(2-hidroxi-fenoxi)-octil-dietanolamida y sales de la misma para el suministro de agentes activos. |
DK1930414T3 (da) * | 2005-09-08 | 2012-10-22 | Medinet Co Ltd | Fremgangsmåde til aktiveringsbehandling af antigenpræsenterende celle |
EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
WO2008152822A1 (ja) * | 2007-06-15 | 2008-12-18 | Medinet Co., Ltd. | 医薬 |
MX2010008099A (es) * | 2008-01-28 | 2010-08-04 | Medimmune Ltd | Anticuerpos y angiopoyetina-2 estabilizados y sus usos. |
AU2009273540A1 (en) * | 2008-07-25 | 2010-01-28 | Merck Patent Gmbh | Method of determination of receptor binding saturation effected by monoclonal antibodies |
WO2010141093A2 (en) * | 2009-06-04 | 2010-12-09 | The University Of Maryland, Baltimore | Co-signaling methods for treating cancers |
WO2011090005A1 (ja) * | 2010-01-19 | 2011-07-28 | 協和発酵キリン株式会社 | 大腸癌の治療用医薬および治療方法 |
-
2012
- 2012-05-23 WO PCT/EP2012/002210 patent/WO2013174403A1/en active Application Filing
-
2013
- 2013-05-21 DK DK13724523.9T patent/DK2852408T3/en active
- 2013-05-21 CN CN201380026482.1A patent/CN104379166B/zh active Active
- 2013-05-21 FI FIEP20194625.8T patent/FI3791896T3/fi active
- 2013-05-21 KR KR1020217006323A patent/KR102625189B1/ko active IP Right Grant
- 2013-05-21 AU AU2013265638A patent/AU2013265638B2/en active Active
- 2013-05-21 ES ES17171169T patent/ES2835073T3/es active Active
- 2013-05-21 LT LTEP13724523.9T patent/LT2852408T/lt unknown
- 2013-05-21 HU HUE17171169A patent/HUE054214T2/hu unknown
- 2013-05-21 UA UAA201413810A patent/UA118013C2/uk unknown
- 2013-05-21 CA CA2874032A patent/CA2874032A1/en active Pending
- 2013-05-21 DK DK20194625.8T patent/DK3791896T3/da active
- 2013-05-21 SI SI201332076T patent/SI3791896T1/sl unknown
- 2013-05-21 KR KR1020247001045A patent/KR20240010757A/ko not_active Application Discontinuation
- 2013-05-21 RS RS20240147A patent/RS65179B1/sr unknown
- 2013-05-21 SI SI201331818T patent/SI3254695T1/sl unknown
- 2013-05-21 WO PCT/EP2013/001504 patent/WO2013174510A1/en active Application Filing
- 2013-05-21 NZ NZ701585A patent/NZ701585A/en not_active IP Right Cessation
- 2013-05-21 KR KR1020147036040A patent/KR102233344B1/ko active IP Right Grant
- 2013-05-21 BR BR112014028948A patent/BR112014028948B8/pt active IP Right Grant
- 2013-05-21 MX MX2014014216A patent/MX2014014216A/es active IP Right Grant
- 2013-05-21 HU HUE13724523A patent/HUE036000T2/hu unknown
- 2013-05-21 LT LTEP20194625.8T patent/LT3791896T/lt unknown
- 2013-05-21 RS RS20201449A patent/RS61127B1/sr unknown
- 2013-05-21 PT PT171711690T patent/PT3254695T/pt unknown
- 2013-05-21 NZ NZ725347A patent/NZ725347A/en unknown
- 2013-05-21 SG SG11201406977TA patent/SG11201406977TA/en unknown
- 2013-05-21 PT PT137245239T patent/PT2852408T/pt unknown
- 2013-05-21 ES ES13724523.9T patent/ES2637416T3/es active Active
- 2013-05-21 LT LTEP17171169.0T patent/LT3254695T/lt unknown
- 2013-05-21 CN CN201811066117.4A patent/CN109172820B/zh active Active
- 2013-05-21 PT PT201946258T patent/PT3791896T/pt unknown
- 2013-05-21 US US14/401,899 patent/US20150132253A1/en not_active Abandoned
- 2013-05-21 RU RU2014152115A patent/RU2665321C2/ru active
- 2013-05-21 JP JP2015513044A patent/JP6203831B2/ja active Active
- 2013-05-21 SG SG10201609772PA patent/SG10201609772PA/en unknown
- 2013-05-21 HR HRP20240169TT patent/HRP20240169T1/hr unknown
- 2013-05-22 AR ARP130101784 patent/AR091130A1/es not_active Application Discontinuation
-
2014
- 2014-11-10 IL IL235607A patent/IL235607A0/en active IP Right Grant
- 2014-11-21 MX MX2020011782A patent/MX2020011782A/es unknown
- 2014-11-21 MX MX2020011771A patent/MX2020011771A/es unknown
- 2014-11-21 MX MX2020011780A patent/MX2020011780A/es unknown
- 2014-11-21 MX MX2019013723A patent/MX2019013723A/es unknown
-
2015
- 2015-09-07 HK HK15108682.9A patent/HK1208152A1/zh unknown
-
2017
- 2017-08-30 JP JP2017165303A patent/JP6490764B2/ja active Active
-
2018
- 2018-02-27 AU AU2018201391A patent/AU2018201391B2/en active Active
- 2018-03-01 US US15/909,577 patent/US20180258180A1/en not_active Abandoned
-
2020
- 2020-11-23 HR HRP20201859TT patent/HRP20201859T1/hr unknown
- 2020-12-09 IL IL279330A patent/IL279330A/en unknown
-
2022
- 2022-05-17 AR ARP220101320A patent/AR125906A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
HK1219486A1 (zh) | 用於治療癌症的涉及抗密蛋白 的抗體的療法 | |
HK1213925A1 (zh) | 用於治療癌症的涉及抗密蛋白 抗體的組合療法 | |
PL3254695T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu | |
RS63738B1 (sr) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
PL2976360T3 (pl) | Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego |